Published in Gut Liver on September 24, 2010
Seroprevalence of Helicobacter pylori infection and gastric mucosal atrophy in Bhutan, a country with a high prevalence of gastric cancer. J Med Microbiol (2013) 0.97
Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer (2012) 0.95
Serum Helicobacter pylori CagA antibody titer as a useful marker for advanced inflammation in the stomach in Japan. J Gastroenterol Hepatol (2014) 0.86
Diagnosis and management of high risk group for gastric cancer. Gut Liver (2015) 0.86
Correlations among endoscopic, histologic and serologic diagnoses for the assessment of atrophic gastritis. J Cancer Prev (2014) 0.86
Clinically relevant anticancer polymer Paclitaxel therapeutics. Cancers (Basel) (2010) 0.84
Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes (2013) 0.82
Prevalence of Helicobacter pylori infection and atrophic gastritis in patients with dyspeptic symptoms in Myanmar. World J Gastroenterol (2015) 0.82
Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease. BMC Clin Pathol (2013) 0.79
Biomarkers for Helicobacter pylori infection and gastroduodenal diseases. Biomark Med (2014) 0.75
The Serum Pepsinogen Test as a Predictor of Kazakh Gastric Cancer. Sci Rep (2017) 0.75
Age-Specific Gastric Cancer Risk Indicated by the Combination of Helicobacter pylori Sero-Status and Serum Pepsinogen Levels. Iran Biomed J (2015) 0.75
Association between Helicobacter pylori and Gastric Cancers. Gut Liver (2017) 0.75
Relationship between ghrelin, Helicobacter pylori and gastric mucosal atrophy in hemodialysis patients. World J Gastroenterol (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat (2005) 11.27
Gastric carcinoma. N Engl J Med (1995) 5.77
Endoscopic resection of early gastric cancer. Gastric Cancer (2007) 4.67
Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology (1982) 3.05
Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer (2004) 2.88
Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology (1992) 2.83
Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol (1995) 2.64
The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol (2008) 2.56
Seroprevalence of Helicobacter pylori in South Korea. Helicobacter (2007) 2.21
Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology (2002) 2.14
Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology (1972) 2.09
Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn (1987) 2.03
Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer (1985) 1.89
Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut (1997) 1.89
Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology (1982) 1.72
Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer (2006) 1.71
Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol (1994) 1.69
Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology (1971) 1.64
Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol (2003) 1.64
Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut (1999) 1.60
Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut (2007) 1.57
Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci (1997) 1.57
Serum pepsinogen I levels and acid secretion in Helicobacter pylori associated enlarged fold gastritis. Ital J Gastroenterol (1997) 1.40
Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin Chim Acta (1982) 1.30
Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer (2003) 1.30
The future of gastric cancer prevention. Gastric Cancer (2004) 1.30
The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol (2006) 1.29
Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol (2010) 1.28
[Gastric cancer screening and diagnosis]. Korean J Gastroenterol (2009) 1.25
Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama study. Arch Intern Med (2000) 1.24
Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut (2009) 1.23
Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomarkers Prev (2006) 1.22
Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol (1996) 1.18
Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival. Langenbecks Arch Surg (2004) 1.17
Serum pepsinogen concentration as a marker of Helicobacter pyloriinfection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol (2003) 1.16
The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter (2008) 1.12
Review article: Relationship between Helicobacter pylori, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther (1998) 1.12
Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci (2006) 1.11
The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res (1989) 1.10
Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol (1998) 1.07
Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis (2005) 1.07
Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter (2008) 1.04
Serum pepsinogen and gastric cancer screening. Intern Med (2007) 1.03
Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in Occidental and Oriental duodenal ulcer patients. Gastroenterology (1988) 1.03
Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev (1993) 1.02
Surgical outcome of 483 patients with early gastric cancer: prognosis, postoperative morbidity and mortality, and gastric remnant cancer. Hepatogastroenterology (2004) 1.00
The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. Gastroenterology (1994) 0.98
Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol (2009) 0.97
Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter (2001) 0.96
Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/or intestinal metaplasia. Helicobacter (2009) 0.95
Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol (2005) 0.94
Helicobacter pylori stimulates pepsin secretion from isolated rabbit gastric glands. Scand J Gastroenterol Suppl (1991) 0.93
Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais. J Gastroenterol (2007) 0.92
Association between gastric cancer mortality and nitrate content of drinking water: ecological study on small area inequalities. Eur J Epidemiol (2001) 0.91
Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol (2004) 0.91
Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen (2006) 0.90
Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. Eur J Gastroenterol Hepatol (2009) 0.89
Protective effect of fruits and vegetables on stomach cancer in a cohort of Swedish twins. Int J Cancer (1998) 0.88
Review article: molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther (2003) 0.88
Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol (2005) 0.88
Helicobacter pylori lipopolysaccharide stimulates gastric mucosal pepsinogen secretion. Aliment Pharmacol Ther (1992) 0.87
Pepsinogens I and II in gastric cancer: an immunohistochemical study using monoclonal antibodies. Jpn J Cancer Res (1988) 0.84
Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J Gastroenterol (2005) 0.82
Salt and gastric cancer. Eur J Cancer Prev (1998) 0.82
Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. Helicobacter (2008) 0.82
Severe atrophic gastritis with Helicobacter pylori infection and gastric cancer. Gastric Cancer (1998) 0.81
The association of smoking and drinking habits with serum pepsinogens. Int J Epidemiol (1995) 0.81
Correlation of serum pepsinogens and gross appearances combined with histology in early gastric cancer. J Exp Clin Cancer Res (2006) 0.81
[Helicobacter pylori and gastric cancer: relationship with histological subtype and tumor location]. Gastroenterol Hepatol (2005) 0.81
Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Eur J Gastroenterol Hepatol (1999) 0.81
Normal serum pepsinogen I levels in adults: a population-based study with special reference to Helicobacter pylori infection and parietal cell antibodies. Scand J Clin Lab Invest (2005) 0.79
Variability in serum pepsinogen levels in an asymptomatic population. Eur J Gastroenterol Hepatol (1995) 0.76
Helicobacter pylori and gastric carcinoma. Prilozi (2007) 0.76
[Relationship between factors examined at health examination and serum pepsinogen levels in healthy adults. Physical measurements, blood chemical tests, drinking and smoking]. Nihon Koshu Eisei Zasshi (1998) 0.76
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms? Gastrointest Endosc (2012) 1.90
Efficacy of computed virtual chromoendoscopy on colorectal cancer screening: a prospective, randomized, back-to-back trial of Fuji Intelligent Color Enhancement versus conventional colonoscopy to compare adenoma miss rates. Gastrointest Endosc (2010) 1.85
Clinical outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Surg Endosc (2009) 1.83
Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter (2011) 1.82
Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol (2009) 1.79
Endoscopic prediction of tumor invasion depth in early gastric cancer. Gastrointest Endosc (2011) 1.78
Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc (2009) 1.68
The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci (2009) 1.65
[Risk factors for development and recurrence of peptic ulcer disease]. Korean J Gastroenterol (2010) 1.59
Incidence and management of colonoscopic perforations in Korea. Digestion (2009) 1.58
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol (2008) 1.58
Detection rate of Helicobacter pylori against a background of atrophic gastritis and/or intestinal metaplasia. J Clin Gastroenterol (2007) 1.55
[Assessment of factors affecting the accuracy of endoscopic ultrasonography in T2 stage gastric cancer]. Korean J Gastroenterol (2008) 1.51
Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation. J Gastroenterol (2002) 1.44
[Effects of proton pump inhibitors in asthmatics with gastroesophageal reflux disease]. Korean J Gastroenterol (2011) 1.42
Clinical features and prognosis of early colorectal cancer treated by endoscopic mucosal resection. J Gastroenterol Hepatol (2011) 1.41
Incidence and risk factors of irritable bowel syndrome in community subjects with culture-proven bacterial gastroenteritis. Korean J Gastroenterol (2012) 1.40
Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter (2012) 1.40
Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol (2010) 1.36
Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol (2013) 1.31
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol (2010) 1.31
Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol (2010) 1.28
The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter (2008) 1.23
Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol (2010) 1.23
Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother (2004) 1.23
Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res (2003) 1.20
Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm Bowel Dis (2006) 1.20
Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer (2008) 1.19
Genes of Helicobacter pylori regulated by attachment to AGS cells. Infect Immun (2004) 1.17
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother (2005) 1.16
Is endoscopic ultrasonography indispensable in patients with early gastric cancer prior to endoscopic resection? Surg Endosc (2010) 1.16
Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol (2006) 1.15
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter (2010) 1.14
The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter (2008) 1.12
Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer. Surg Endosc (2012) 1.12
Clinical outcome of pylorus-preserving gastrectomy in gastric cancer in comparison with conventional distal gastrectomy with Billroth I anastomosis. World J Surg (2008) 1.11
The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. J Clin Gastroenterol (2009) 1.11
Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci (2006) 1.11
Effect of annual endoscopic screening on clinicopathologic characteristics and treatment modality of gastric cancer in a high-incidence region of Korea. Int J Cancer (2012) 1.08
Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents (2006) 1.07
CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. J Korean Med Sci (2011) 1.06
Prevalence and risk of colorectal adenoma in asymptomatic Koreans aged 40-49 years undergoing screening colonoscopy. J Gastroenterol Hepatol (2010) 1.05
Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J Microbiol Biotechnol (2008) 1.05
Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter (2009) 1.04
Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter (2008) 1.04
Histologic characteristics of gastric polyps in Korea: emphasis on discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimen. World J Gastroenterol (2006) 1.02
Vacuolating cytotoxin in Helicobacter pylori water-soluble proteins upregulates chemokine expression in human eosinophils via Ca2+ influx, mitochondrial reactive oxygen intermediates, and NF-kappaB activation. Infect Immun (2007) 1.02
Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter (2007) 1.02
The effects of genetic polymorphisms of IL-1 and TNF-A on Helicobacter pylori-induced gastroduodenal diseases in Korea. Helicobacter (2006) 1.02
The prevalence of and risk factors for Barrett's esophagus in a Korean population: A nationwide multicenter prospective study. J Clin Gastroenterol (2009) 1.02
Clinicopathologic features of asymptomatic gastric adenocarcinoma patients in Korea. Jpn J Clin Oncol (2004) 1.02
Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol (2008) 1.02
Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol (2012) 1.00
Effect of aging on gastric mucosal defense mechanisms: ROS, apoptosis, angiogenesis, and sensory neurons. Am J Physiol Gastrointest Liver Physiol (2010) 1.00
Association between alcohol intake and risk for gastric cancer with regard to ALDH2 genotype in the Korean population. Int J Epidemiol (2011) 1.00
Effect of Helicobacter pylori Eradication on Functional Dyspepsia. J Neurogastroenterol Motil (2013) 1.00
Long-term outcome in patients with obscure gastrointestinal bleeding after negative capsule endoscopy. World J Gastroenterol (2013) 0.99
Fundamental role of ClC-3 in volume-sensitive Cl- channel function and cell volume regulation in AGS cells. Am J Physiol Gastrointest Liver Physiol (2003) 0.98
Effect of inhibition of extracellular signal-regulated kinase 1 and 2 pathway on apoptosis and bcl-2 expression in Helicobacter pylori-infected AGS cells. Infect Immun (2003) 0.98
Prospective evaluation of a new stool antigen test for the detection of Helicobacter pylori, in comparison with histology, rapid urease test, (13)C-urea breath test, and serology. J Gastroenterol Hepatol (2011) 0.97
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea]. Korean J Gastroenterol (2011) 0.97
Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter (2012) 0.97
Long-term clinical outcome of helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma is comparable to that of h. pylori-positive lymphoma. J Clin Gastroenterol (2009) 0.96
[The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years]. Korean J Gastroenterol (2006) 0.96
Gastroprotective action of Cochinchina momordica seed extract is mediated by activation of CGRP and inhibition of cPLA(2)/5-LOX pathway. Dig Dis Sci (2009) 0.96
Role of Helicobacter pylori infection in aberrant DNA methylation along multistep gastric carcinogenesis. Cancer Sci (2010) 0.96
Helicobacter pylori infection activates NF-kappaB signaling pathway to induce iNOS and protect human gastric epithelial cells from apoptosis. Am J Physiol Gastrointest Liver Physiol (2003) 0.96
Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol (2014) 0.96
Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter (2013) 0.96
Clinical outcomes and patency of self-expanding metal stents in patients with malignant upper gastrointestinal obstruction. Dig Dis Sci (2007) 0.96
Clinical spectrum of reflux esophagitis among 25,536 Koreans who underwent a health check-up: a nationwide multicenter prospective, endoscopy-based study. J Clin Gastroenterol (2009) 0.95
Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci (2014) 0.95
Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci (2012) 0.95
Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/or intestinal metaplasia. Helicobacter (2009) 0.95
Association of sleep dysfunction and emotional status with gastroesophageal reflux disease in Korea. J Neurogastroenterol Motil (2013) 0.95
Prevalence and clinicopathologic characteristics of gastric cardia cancer in South Korea. Helicobacter (2012) 0.94
Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol (2006) 0.94
Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea. J Gastroenterol Hepatol (2009) 0.93
Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol (2009) 0.93
Analysis of the 3' variable region of the cagA gene of Helicobacter pylori isolated in Koreans. Dig Dis Sci (2007) 0.93
Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol (2008) 0.93
Clinical outcomes and patency of self-expanding metal stents in patients with malignant colorectal obstruction: a prospective single center study. Int J Colorectal Dis (2008) 0.93
Intrafamilial aggregation of gastric cancer: a comprehensive approach including environmental factors, Helicobacter pylori virulence, and genetic susceptibility. Eur J Gastroenterol Hepatol (2011) 0.93
Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver (2009) 0.92
Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer. Hepatogastroenterology (2012) 0.91
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea]. Korean J Gastroenterol (2011) 0.91
Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter (2006) 0.91
The interleukin-8-251 A allele is associated with increased risk of noncardia gastric adenocarcinoma in Helicobacter pylori-infected Koreans. J Clin Gastroenterol (2009) 0.91
Prediction of risk of malignancy of gastrointestinal stromal tumors by endoscopic ultrasonography. Gut Liver (2013) 0.91
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci (2007) 0.91
Lymph node metastasis in multiple synchronous early gastric cancer. Gastrointest Endosc (2011) 0.90
[Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003]. Korean J Gastroenterol (2004) 0.90
Up-regulation of inducible nitric oxide synthase and nitric oxide in Helicobacter pylori-infected human gastric epithelial cells: possible role of interferon-gamma in polarized nitric oxide secretion. Helicobacter (2002) 0.90
Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. Eur J Gastroenterol Hepatol (2009) 0.89
Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.89
Incidental colonic 18F-fluorodeoxyglucose uptake: do we need colonoscopy for patients with focal uptake confined to the left-sided colon? Dig Dis Sci (2012) 0.88
Seroconversion of Helicobacter pylori in Korean male employees. Scand J Gastroenterol (2005) 0.88
Gastric mucosal protection via enhancement of MUC5AC and MUC6 by geranylgeranylacetone. Dig Dis Sci (2005) 0.88
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter (2007) 0.88